Seeking Alpha

The FDA has approved Teva's (TEVA -0.6%) Synribo to treat adults with chronic myelogenous...

The FDA has approved Teva's (TEVA -0.6%) Synribo to treat adults with chronic myelogenous leukemia, a blood and bone marrow disease. The drug is intended to be used in patients whose cancer progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors, also used to treat the disease.
Comments (2)
  • Given the market reaction: So what!?
    26 Oct 2012, 11:34 AM Reply Like
  • Can anybody explain the behavior of Teva's equity ???
    26 Oct 2012, 12:28 PM Reply Like
DJIA (DIA) S&P 500 (SPY)